Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers

Annegien Broeks; Lot De Witte; Anke Nooijen; Angelina Huseinovic; Jan G.M. Klijn; Flora E. Van Leeuwen; Nicola S. Russell; Laura J. Van't Veer

doi:10.1023/B:BREA.0000010697.49896.03

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers

Annegien Broeks
, Lot De Witte
, Anke Nooijen
, Angelina Huseinovic
, Jan G.M. Klijn
, Flora E. Van Leeuwen
, Nicola S. Russell
, Laura J. Van't Veer

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.

Original language	English
Pages (from-to)	91-93
Number of pages	3
Journal	Breast Cancer Research and Treatment
Volume	83
Issue number	1
DOIs	https://doi.org/10.1023/B:BREA.0000010697.49896.03
State	Published - Jan 2004
Externally published	Yes

Keywords

Breast cancer
CHEK2
Contralateral
Mutation
Radiation

Access to Document

10.1023/B:BREA.0000010697.49896.03

Cite this

@article{8f11fe48a14244469e67b307d0ada20c,

title = "Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers",

abstract = "We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95\% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.",

keywords = "Breast cancer, CHEK2, Contralateral, Mutation, Radiation",

author = "Annegien Broeks and \{De Witte\}, Lot and Anke Nooijen and Angelina Huseinovic and Klijn, \{Jan G.M.\} and \{Van Leeuwen\}, \{Flora E.\} and Russell, \{Nicola S.\} and \{Van't Veer\}, \{Laura J.\}",

year = "2004",

month = jan,

doi = "10.1023/B:BREA.0000010697.49896.03",

language = "English",

volume = "83",

pages = "91--93",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers

AU - Broeks, Annegien

AU - De Witte, Lot

AU - Nooijen, Anke

AU - Huseinovic, Angelina

AU - Klijn, Jan G.M.

AU - Van Leeuwen, Flora E.

AU - Russell, Nicola S.

AU - Van't Veer, Laura J.

PY - 2004/1

Y1 - 2004/1

N2 - We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.

AB - We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.

KW - Breast cancer

KW - CHEK2

KW - Contralateral

KW - Mutation

KW - Radiation

UR - https://www.scopus.com/pages/publications/0942279575

U2 - 10.1023/B:BREA.0000010697.49896.03

DO - 10.1023/B:BREA.0000010697.49896.03

M3 - Article

C2 - 14997059

AN - SCOPUS:0942279575

SN - 0167-6806

VL - 83

SP - 91

EP - 93

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers

Abstract

Keywords

Access to Document

Fingerprint

Cite this